Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1017/s1092852900022720 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The SNABB ADHD treatment scale-An easy-to-use scale on treatment monitoring in childhood ADHD: A pilot study.
Front Child Adolesc Psychiatry
April 2023
Child and Adolescent Specialist Centre, Angered Hospital, SV Hospital Group, Gothenburg, Sweden.
Introduction: Information from parents and teachers are essential in the treatment monitoring of children with attention deficit hyperactivity disorder (ADHD). Rating scales are infrequently used in the treatment monitoring, and clinicians are signalling logistic barriers in the administration of rating scales in clinical settings. Here, we aimed to try out a new easy-to-use scale to facilitate information sharing between parents, teachers, and medical staff, in the treatment of childhood ADHD.
View Article and Find Full Text PDFCutting through the noise: A narrative review of Alzheimer's disease plasma biomarkers for routine clinical use.
J Prev Alzheimers Dis
January 2025
Clinical Memory Research Unit, Clinical Sciences in Malmö, Lund University, Lund, Sweden; Memory Clinic, Skåne University Hospital, Sweden. Electronic address:
As novel, anti-amyloid therapies have become more widely available, access to timely and accurate diagnosis has become integral to ensuring optimal treatment of patients with early-stage Alzheimer's disease (AD). Plasma biomarkers are a promising tool for identifying AD pathology; however, several technical and clinical factors need to be considered prior to their implementation in routine clinical use. Given the rapid pace of advancements in the field and the wide array of available biomarkers and tests, this review aims to summarize these considerations, evaluate available platforms, and discuss the steps needed to bring plasma biomarker testing to the clinic.
View Article and Find Full Text PDFMyokines and the Brain: A Novel Neuromuscular Endocrine Loop.
J Neuropsychiatry Clin Neurosci
January 2025
Veterans Affairs Mid-Atlantic Mental Illness Research, Education and Clinical Center and the Research and Academic Affairs Service Line, W. G. Hefner Veterans Affairs Medical Center, Salisbury, N.C. (López-Ojeda, Hurley); Department of Psychiatry and Behavioral Medicine (López-Ojeda, Hurley) and Department of Radiology (Hurley), Wake Forest University School of Medicine, Winston-Salem, N.C.
A Note of Gratitude to C. Alan Anderson, M.D., Deputy Editor, .
J Neuropsychiatry Clin Neurosci
January 2025
Editor, Journal of Neuropsychiatry and Clinical Neurosciences, and Cooper Neuropsychiatry Scholar and Professor, Department of Neurology, University of Colorado School of Medicine, Aurora.
Cenobamate as add-on treatment for SCN8A developmental and epileptic encephalopathy.
Epilepsia
January 2025
Department of Epilepsy Genetics and Personalized Medicine, Danish Epilepsy Center, Dianalund, Denmark.
Objectives: Developmental and epileptic encephalopathies (DEEs) caused by pathogenic variants in SCN8A are associated with difficult-to-treat and early-onset seizures, developmental delay/intellectual disability, impaired quality of life, and increased risk of early mortality. High doses of sodium channel blockers are typically used to treat SCN8A-DEE caused by gain-of-function (GoF) variants. However, seizures are often drug resistant, and only a few patients achieve seizure freedom.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!